Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines

Table 2 The vicissitudes of the recommendation categories of different neoadjuvant chemotherapy regimens in the NCCN gastric cancer guidelines

	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019.V1	2019. V2
ECF[14]	1	1	1	1	1	1	1	1	1	2B	2B
ECF modifications[39,40]		1	1	1	1	1	1	2A	2A	2B	2B
Fluorouracil and cisplatin[16]							1	1	1	1	1	1	1	1
aFluorouracil and oxaliplatin[19-21]											2A	2Ab	2Ab	2Ab
FLOT[17]												1b	1b	1b

References quoted in Table 2 for each regimen were based on NCCN guidelines from 2007 to 2019. 1, 2A, 2B: Categories of recommendations.

^b: Preferred intervention.

^a: This regimen was based on extrapolations from literature and clinical practice according to NCCN guidelines, and was revised to fluoropyrimidine and oxaliplatin in 2017 NCCN guidelines. ECF: Epirubicin, cisplatin, and fluorouracil; FLOT: Docetaxel, fluorouracil, leucovorin, and oxaliplatin.